{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T09:44:48Z","timestamp":1790934288008,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,10,9]],"date-time":"2018-10-09T00:00:00Z","timestamp":1539043200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013170","name":"Ono Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013170","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.ejca.2018.09.025","type":"journal-article","created":{"date-parts":[[2018,11,15]],"date-time":"2018-11-15T09:39:56Z","timestamp":1542274796000},"page":"114-126","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":70,"special_numbering":"C","title":["Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II study"],"prefix":"10.1016","volume":"105","author":[{"given":"Kenjiro","family":"Namikawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshio","family":"Kiyohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Takenouchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Uhara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Uchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shusuke","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumiko","family":"Takatsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Koga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Wada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironobu","family":"Minami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Hatsumichi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suguru","family":"Asada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinobu","family":"Namba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoya","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2018.09.025_bib1","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/ni.2762","article-title":"A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application","volume":"14","author":"Okazaki","year":"2013","journal-title":"Nat Immunol"},{"key":"10.1016\/j.ejca.2018.09.025_bib2","doi-asserted-by":"crossref","first-page":"80855","DOI":"10.18632\/oncotarget.12644","article-title":"Pharmacological interventions for melanoma: comparative analysis using Bayesian meta-analysis","volume":"7","author":"Yang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejca.2018.09.025_bib3","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1073\/pnas.0915174107","article-title":"PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors","volume":"107","author":"Curran","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"15_Suppl","key":"10.1016\/j.ejca.2018.09.025_bib4","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1200\/jco.2013.31.15_suppl.3061","article-title":"Antitumor activity of concurrent blockade of immune checkpoint molecules CTLA-4 and PD-1 in preclinical models","author":"Selby","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2018.09.025_bib5","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma","volume":"369","author":"Wolchok","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2018.09.025_bib6","doi-asserted-by":"crossref","first-page":"5s","DOI":"10.1200\/jco.2014.32.18_suppl.lba9003","article-title":"Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL)","volume":"32","author":"Sznol","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2018.09.025_bib7","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2018.09.025_bib8","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S1470-2045(16)30366-7","article-title":"Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial","volume":"17","author":"Hodi","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2018.09.025_bib9","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2018.09.025_bib10","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2018.09.025_bib11","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ejca.2017.06.028","article-title":"Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017","volume":"83","author":"Ugurel","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2018.09.025_bib12","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1056\/NEJMoa050092","article-title":"Distinct sets of genetic alterations in melanoma","volume":"353","author":"Curtin","year":"2005","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.ejca.2018.09.025_bib13","doi-asserted-by":"crossref","first-page":"4340","DOI":"10.1200\/JCO.2006.06.2984","article-title":"Somatic activation of KIT in distinct subtypes of melanoma","volume":"24","author":"Curtin","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2018.09.025_bib14","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/CMR.0000000000000375","article-title":"Characteristics of melanoma in Japan: a nationwide registry analysis 2011\u20132013","volume":"27","author":"Tomizuka","year":"2017","journal-title":"Melanoma Res"},{"key":"10.1016\/j.ejca.2018.09.025_bib15","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s10147-007-0751-1","article-title":"Statistical profiles of malignant melanoma and other skin cancers in Japan: 2007 update","volume":"13","author":"Ishihara","year":"2008","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.ejca.2018.09.025_bib16","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.hoc.2014.02.007","article-title":"Understanding the biology of melanoma and therapeutic implications","volume":"28","author":"Sullivan","year":"2014","journal-title":"Hematol Oncol Clin N Am"},{"key":"10.1016\/j.ejca.2018.09.025_bib17","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jdermsci.2015.07.012","article-title":"Clinical characteristics associated with BRAF, NRAS and KIT mutations in Japanese melanoma patients","volume":"80","author":"Sakaizawa","year":"2015","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.ejca.2018.09.025_bib18","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/CMR.0000000000000091","article-title":"BRAF V600 mutations and pathological features in Japanese melanoma patients","volume":"25","author":"Yamazaki","year":"2015","journal-title":"Melanoma Res"},{"key":"10.1016\/j.ejca.2018.09.025_bib19","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1002\/cncr.30259","article-title":"The efficacy of anti-PD-1 agents in acral and mucosal melanoma","volume":"122","author":"Shoushtari","year":"2016","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2018.09.025_bib20","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1200\/JCO.2016.67.9258","article-title":"Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: a pooled analysis","volume":"35","author":"D'Angelo","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2018.09.025_bib21","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2018.09.025_bib22","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s00280-015-2870-0","article-title":"Phase II study of the immune-checkpoint inhibitor ipilimumab plus dacarbazine in Japanese patients with previously untreated, unresectable or metastatic melanoma","volume":"76","author":"Yamazaki","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ejca.2018.09.025_bib23","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1634\/theoncologist.2015-0522","article-title":"Prognosis of mucosal, uveal, acral, nonacral cutaneous, and unknown primary melanoma from the time of first metastasis","volume":"21","author":"Kuk","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2018.09.025_bib24","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1111\/pcmr.12279","article-title":"The mutational burden of acral melanoma revealed by whole-genome sequencing and comparative analysis","volume":"27","author":"Furney","year":"2014","journal-title":"Pigment Cell Melanoma Res"},{"issue":"3","key":"10.1016\/j.ejca.2018.09.025_bib25","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/path.4204","article-title":"Genome sequencing of mucosal melanomas reveals that they are driven by distinct mechanisms from cutaneous melanoma","volume":"230","author":"Furney","year":"2013","journal-title":"J Pathol"},{"key":"10.1016\/j.ejca.2018.09.025_bib26","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nature22071","article-title":"Whole-genome landscapes of major melanoma subtypes","volume":"545","author":"Hayward","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2018.09.025_bib27","first-page":"27","article-title":"Genotyping of cutaneous melanoma","volume":"3","author":"Glitza","year":"2014","journal-title":"Chin Clin Oncol"},{"key":"10.1016\/j.ejca.2018.09.025_bib28","first-page":"1230","article-title":"Ocular melanoma: an overview of the current status","volume":"6","author":"Jovanovic","year":"2013","journal-title":"Int J Clin Exp Pathol"},{"key":"10.1016\/j.ejca.2018.09.025_bib29","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1093\/annonc\/mdx108","article-title":"Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab","volume":"28","author":"Chaput","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2018.09.025_bib30","series-title":"Opdivo: EPAR \u2013 product information","author":"European Medicines Agency","year":"2018"},{"issue":"6","key":"10.1016\/j.ejca.2018.09.025_bib31","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1111\/cas.13241","article-title":"Efficacy and safety of nivolumab in Japanese patients with previously untreated advanced melanoma: a phase II study","volume":"108","author":"Yamazaki","year":"2017","journal-title":"Cancer Sci"},{"key":"10.1016\/j.ejca.2018.09.025_bib32","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1093\/annonc\/mdt161","article-title":"Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials","volume":"24","author":"Wolchok","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2018.09.025_bib33","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.76.8275","article-title":"Duration of anti-programmed death-1 therapy in advanced melanoma: how much of a good thing is enough?","author":"Khushalani","year":"2018","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918313959?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918313959?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:22:37Z","timestamp":1760732557000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804918313959"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":33,"alternative-id":["S0959804918313959"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2018.09.025","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2018.09.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}